CIM LLC’s Catalyst Pharmaceutical CPRX Stock Holding History

CIM LLC’s Portfolio CPRX Stock Details CPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$558K	Hold	22,556	–	–	0.08%	111
2025 Q4	$526K	Sell	22,556 -777	-3%	-$17.3K	0.07%	118
2025 Q3	$460K	Hold	23,333	–	–	0.06%	127
2025 Q2	$506K	Sell	23,333 -2,511	-10%	-$59.3K	0.07%	115
2025 Q1	$627K	Sell	25,844 -1,195	-4%	-$26.9K	0.09%	105
2024 Q4	$564K	Sell	27,039 -28	-0.1%	-$602	0.08%	115
2024 Q3	$538K	Sell	27,067 -180	-0.7%	-$3.34K	0.08%	112
2024 Q2	$540K	Sell	27,247 -104	-0.4%	-$1.62K	0.08%	108
2024 Q1	$436K	Buy	27,351 +188	+0.7%	+$2.83K	0.07%	111
2023 Q4	$378K	Buy	27,163 +2,250	+9%	+$30.8K	0.06%	115
2023 Q3	$291K	Buy	24,913 +871	+4%	+$11.7K	0.06%	122
2023 Q2	$323K	Buy	24,042 +1,286	+6%	+$18.5K	0.06%	125
2023 Q1	$377K	Sell	22,756 -640	-3%	-$10.6K	0.07%	113
2022 Q4	$362K	Sell	23,396 -923	-4%	-$14.2K	0.07%	121
2022 Q3	$340K	Buy	+24,319	New	+$288K	0.07%	124

Other funds holding CPRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

CIM LLC's CPRX Position: Q1 2026 in Review

CIM LLC held its Catalyst Pharmaceutical (CPRX) position steady in Q1 2026 at 22,556 shares worth $558K. The position accounts for 0.08% of the portfolio, ranked #111.

CIM LLC first reported a position in CPRX in Q3 2022 and has held it in 15 quarters since. The position peaked at $627K in Q1 2025. 380 funds tracked by Wall St. Rank hold CPRX as of Q1 2026.

CIM LLC held 22,556 shares of Catalyst Pharmaceutical worth $558K as of Q1 2026.
CIM LLC left its Catalyst Pharmaceutical share count unchanged in Q1 2026.
Catalyst Pharmaceutical made up 0.08% of CIM LLC's portfolio in Q1 2026, its #111 holding.
CIM LLC first reported a position in Catalyst Pharmaceutical in Q3 2022 and has held it in 15 quarters since.
CIM LLC's Catalyst Pharmaceutical position peaked at $627K in Q1 2025.
380 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2026.

Based on CIM LLC's 13F filing for Q1 2026, filed 18 May 2026.